HomeComparePROSF vs JNJ

PROSF vs JNJ: Dividend Comparison 2026

PROSF yields 0.51% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PROSF wins by $643.1K in total portfolio value
10 years
PROSF
PROSF
● Live price
0.51%
Share price
$45.00
Annual div
$0.23
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$673.3K
Annual income
$490,172.20
Full PROSF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — PROSF vs JNJ

📍 PROSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPROSFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PROSF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PROSF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PROSF
Annual income on $10K today (after 15% tax)
$43.70/yr
After 10yr DRIP, annual income (after tax)
$416,646.37/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, PROSF beats the other by $412,660.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PROSF + JNJ for your $10,000?

PROSF: 50%JNJ: 50%
100% JNJ50/50100% PROSF
Portfolio after 10yr
$351.8K
Annual income
$247,430.80/yr
Blended yield
70.33%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

PROSF
No analyst data
Altman Z
4.8
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PROSF buys
0
JNJ buys
0
No recent congressional trades found for PROSF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPROSFJNJ
Forward yield0.51%2.13%
Annual dividend / share$0.23$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$673.3K$30.3K
Annual income after 10y$490,172.20$4,689.40
Total dividends collected$637.2K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PROSF vs JNJ ($10,000, DRIP)

YearPROSF PortfolioPROSF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,803$102.82$10,592$272.30+$211.00PROSF
2$11,767$207.62$11,289$357.73+$478.00PROSF
3$13,013$422.70$12,123$472.89+$890.00PROSF
4$14,798$873.78$13,141$629.86+$1.7KPROSF
5$17,691$1,857.23$14,408$846.81+$3.3KPROSF
6$23,079$4,150.16$16,021$1,151.60+$7.1KPROSF
7$34,815$10,120.14$18,122$1,588.22+$16.7KPROSF
8$65,787$28,534.91$20,930$2,228.20+$44.9KPROSF
9$171,177$100,785.11$24,792$3,191.91+$146.4KPROSF
10$673,332$490,172.20$30,274$4,689.40+$643.1KPROSF

PROSF vs JNJ: Complete Analysis 2026

PROSFStock

Prosus N.V. engages in the e-commerce and internet businesses. The company operates internet platforms, such as classifieds, payments and fintech, food delivery, travel, education technology, etail, health, ventures, social, and other internet platforms. It has operations in Latin and North America, the Middle East, Africa, Europe, Asia, and internationally. The company was formerly known as Myriad International Holdings N.V. and changed its name to Prosus N.V. in August 2019. Prosus N.V. was incorporated in 1994 and is headquartered in Amsterdam, the Netherlands. Prosus N.V. is a subsidiary of Naspers Limited.

Full PROSF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this PROSF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PROSF vs SCHDPROSF vs JEPIPROSF vs OPROSF vs KOPROSF vs MAINPROSF vs ABBVPROSF vs MRKPROSF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.